Where does Viking Therapeutics's income statement data come from?

Every line is extracted from Viking Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$0—	$0—	$0—	$0—	$0—
Research and development	$453.72M+281%	$344.96M+239%	$222.48M+144%	$155.32M+79.0%	$118.93M+54.7%
General and administrative	$48.28M-9.6%	$48.39M-1.8%	$52.36M+22.3%	$57.52M+51.7%	$53.39M+42.5%
Other operating expenses	$502M+191%	$393.34M+161%	$274.84M+105%	$212.84M+70.7%	$172.32M+50.7%
Total operating expenses	$502M+191%	$393.34M+161%	$274.84M+105%	$212.84M+70.7%	$172.32M+50.7%
Operating income	-$502M-191%	-$393.34M-161%	-$274.84M-105%	-$212.84M-70.7%	-$172.32M-50.7%
Interest expense	$29.64M-32.7%	$33.7M-17.7%	$37.51M+7.8%	$41.27M+47.4%	$44.06M+113%
Other income (expense), net	$29.66M-32.7%	$33.7M-17.7%	$37.45M+7.6%	$41.29M+47.8%	$44.08M+114%
Net investment gains (losses)	——	$55K-50.9%	$42.25K-61.9%	$137.5K+6,775%	$125.75K—
Net income	-$472.34M-268%	-$359.64M-227%	-$237.39M-139%	-$171.55M-77.3%	-$128.24M-36.8%
Diluted earnings per share	-$4.15-261%	-$3.19-219%	-$2.12-128%	-$1.53-62.8%	-$1.15-23.7%
Basic earnings per share	-$4.15-261%	-$3.19-219%	-$2.12-128%	-$1.53-62.8%	-$1.15-23.7%
Weighted-average shares, diluted	452.7M+2.3%	449.2M+3.5%	445.6M+6.3%	444.2M+8.8%	442.4M+11.5%
Weighted-average shares, basic	452.7M+2.3%	449.2M+3.5%	445.6M+6.3%	444.2M+8.8%	442.4M+11.5%
Interest Income (Expense), Nonoperating	$29.64M-32.7%	$33.7M-17.7%	$37.51M+7.8%	$41.27M+47.4%	$44.06M+113%
Amortization Of Financing Costs Equity Transactions	$32K-64.4%	$56K-40.4%	$80K-16.7%	$96K+29.7%	$90K+2.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$472.98M-273%	-$358.47M-225%	-$238.65M-147%	-$169.44M-72.9%	-$126.85M-34.0%
Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax	$54K+141%	$47K+121%	-$135K—	-$133K—	-$131K—
Net unrealized gains (losses) on securities still held	-$684K-145%	$1.13M+749%	-$1.12M-145%	$2.24M+292%	$1.51M+271%
Other income, net (Note 6)	$29.66M-32.7%	$33.7M-17.7%	$37.45M+7.6%	$41.29M+47.8%	$44.08M+114%
Revenue From Contract With Customer Excluding Assessed Tax	$0—	$0—	$0—	$0—	$0—
EBIT	-$502M-191%	-$393.34M-161%	-$274.84M-105%	-$212.84M-70.7%	-$172.32M-50.7%
EBIT	-$502M-191%	-$393.34M-161%	-$274.84M-105%	-$212.84M-70.7%	-$172.32M-50.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Viking Therapeutics's income statement data come from?: Every line is extracted from Viking Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.